Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
5-Amino-1MQ
5-amino-1-methylquinolinium, NNMT inhibitor
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's that showed remarkable weight loss in Phase 2 trials. Now being developed specifically for obesity.
A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that regulates fat cell metabolism and NAD+ availability. While technically a small molecule rather than a peptide, it is commonly grouped with peptide therapies in the metabolic health space due to its mechanism and delivery method.
Inhibits reuptake of serotonin, norepinephrine, and dopamine, reducing appetite and increasing energy expenditure through central nervous system modulation. Different mechanism than GLP-1 agonists.
Inhibits NNMT, which normally converts NAD+ precursors into methylnicotinamide — a metabolic dead end. By blocking NNMT, 5-Amino-1MQ increases NAD+ availability in fat cells, activating SIRT1 and promoting fat oxidation. Reduces fat cell size and inhibits new fat cell formation (adipogenesis).
- Weight management (investigational)
- Appetite suppression
- Metabolic rate enhancement
- Fat loss and body composition
- Metabolic health improvement
- Obesity treatment (investigational)
- NAD+ pathway optimization
- Increased heart rate
- Dry mouth
- Insomnia
- Constipation
- Potential cardiovascular concerns
- Not yet approved — full safety profile unknown
- Very limited human clinical data
- Long-term safety unknown
- Optimal dosing not established
- Potential off-target effects of NNMT inhibition not fully characterized
- Often sourced from gray-market vendors with variable quality
Phase 3 clinical trials ongoing. Phase 2 showed up to 12.8% body weight loss at 24 weeks. Approved in Mexico (2024). Not FDA-approved in the US.
Not FDA-approved and not on any compounding list. Available as a research chemical. Growing interest in the metabolic health community but human clinical trial data is extremely limited. Not a peptide in the strict sense — a small molecule — but commonly discussed alongside peptide therapies.
- Tesofensine for treatment of obesity
2008 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.